We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SCHOTT Increases Production of Polymer Syringes by 50 %

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SCHOTT Increases Production of Polymer Syringes by 50 %"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SCHOTT is currently expanding the manufacturing capacity for its SCHOTT TopPac® prefillable polymer syringes to address increasing customer demand. The new production line will be installed at the company’s center of excellence for Pre-fillable syringes in St. Gallen, Switzerland. This move will offer a greater degree of flexibility for customers and further strengthen the importance of the Swiss site which focuses on both, glass and polymer syringes.

“The demand for our polymer syringes has increased since customers appreciate the versatile advantages of the material: It’s break resistant and lightweight, yet has a glass-like transparency. And the excellent barrier properties of the SCHOTT TopPac® syringe system keep the drug stable over shelf life”, says Anil-Kumar Busimi, Head of Global Product Management Syringe Business.

The new production line will seamlessly be integrated in SCHOTT’s existing setup which uses advanced technologies.

SCHOTT TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection-molding to the final packaging in nest and tub. The syringes are sterilized and are ready for aseptic filling operations.

Complete Syringe Portfolio

SCHOTT has been manufacturing glass and polymer syringes in Europe since 1996. Today, the production is concentrated in Switzerland and is supported by an R&D team based at the site. From here SCHOTT has developed a complete portfolio of both glass and polymer syringes. This offers pharma companies a broad range of solutions, suitable for a variety of applications like heparin, vaccines, biotech, and special applications such as intensive care.

In the field of glass syringes, the offerings range from 0.5 to 3 Milliliter products marketed under the brand name syriQ®. All glass syringes are available with luer lock, luer cone or with staked needle.

SCHOTT TopPac® polymer syringes, in turn, are available in the range from 1ml to 50ml with cross linked silicone for optimal functionality. In addition, the company has recently introduced an innovative polymer syringe designed to improve the safety of sensitive drugs: the new product named SCHOTT TopPac® SD offers new features for a reduced E&L (extractables and leachables) profile and ensures high drug stability.